The State of Evidence in Prostate Artery Embolization

Author:

Qamhawi Zahi1,Little Mark W.1

Affiliation:

1. University Department of Radiology, Royal Berkshire Hospital, Reading, United Kingdom

Abstract

AbstractProstate artery embolization (PAE) has emerged over the past two decades as a minimally invasive, nonsurgical treatment for benign prostatic hypertrophy (BPH). While the majority of evidence for PAE stems from retrospective cohort studies, several seminal randomized controlled trials have been performed comparing short-term outcomes of PAE to transurethral resection of prostate (TURP) and against a sham procedure. Across clinical trials, PAE demonstrates consistent improvement in urological symptoms and quality of life in patients with BPH with low complication rates. When compared to TURP, the results are comparable, but there is a trend for better outcomes in certain clinical parameters with TURP. PAE is a suitable option for patients who are not surgical candidates, prefer nonsurgical treatment with an earlier return to routine activities, and wish to better preserve sexual function.

Publisher

Georg Thieme Verlag KG

Subject

Cardiology and Cardiovascular Medicine,Radiology, Nuclear Medicine and imaging

Reference32 articles.

1. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates;K B Egan;Urol Clin North Am,2016

2. Modern best practice in the management of benign prostatic hyperplasia in the elderly;E Bortnick;Ther Adv Urol,2020

3. The morbidity associated with a TURP procedure in routine clinical practice, as graded by the modified Clavien-Dindo system;E Sagen;Scand J Urol,2019

4. Prostatic artery embolization (PAE) for symptomatic benign prostatic hyperplasia (BPH): part 2, insights into the technical rationale;F Sun;Cardiovasc Intervent Radiol,2016

5. Prostatic artery embolization versus transurethral resection of the prostate for benign prostatic hyperplasia: a cost-effectiveness analysis;X Wu;J Vasc Interv Radiol,2022

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3